Cherwell makes an impact with new continuous monitoring microbial air samplers
The new ImpactAir high performance microbial air sampler.
ImpactAir high performance air sampler range joins Cherwell’s portfolio of cleanroom microbiology products.
Cherwell Laboratories has signed a distribution agreement with Pinpoint Scientific for the ImpactAir range of microbial air samplers. The new ImpactAir range of high performance microbial air samplers has been designed to meet the demanding environmental monitoring requirements of aseptic processing in the pharmaceutical and healthcare industries.
ImpactAir is a state-of-the-art range of slit-to-agar microbial air samplers that fully complements Cherwell’s existing portfolio of environmental monitoring products, including SAS microbial air samplers and Redipor prepared microbiological media range. Whereas SAS samplers are ideal for rapid and frequent routine sampling regimes, ImpactAir is designed for continuous monitoring in high-grade areas where in-process sampling of viable particles is critical. Due to its unique design, ImpactAir does not shed particles, so it can be used alongside particle counting devices, and as it runs with extremely low levels of vibration, it can also be operated near balances.
By using larger 140-mm petri dishes, such as those in the Redipor range, the ImpactAir can continuously sample to a single dish over longer periods. This sampling time can be easily programmed on the touch screen user interface, from minutes up to several hours, depending on the process to be monitored. The petri dish rotates slowly under the inlet slit to present fresh agar throughout– dramatically reducing the probability of ‘twin impingement’ (where two microbes impact on an agar plate at the same point to incubate as a single colony) for enhanced accuracy and enabling an estimate of any event times during key processes.
ImpactAir is the first sampler of its kind to employ precision sensing and control to automatically adjust and maintain the distance between air inlet and agar surface, further enhancing sampling efficiency. Critically, this ensures a consistent d50 value of <0.5µm is maintained throughout an entire sampling run, as independently verified by Public Health England (PHE) following physical and biological validation.
Andy Whittard, Cherwell’s Managing Director, commented, “The new ImpactAir microbial air sampler is an exciting addition to our ‘cleanroom microbiology solutions’ offering. It fully supports our existing portfolio of quality environmental monitoring products for our pharma customers. Effective viable monitoring within high-grade areas is vitally important and ImpactAir allows users to perform high efficiency, continuous environmental monitoring. We look forward to working with the manufacturer, Pinpoint Scientific, in developing the UK and Irish markets.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.